冠状动脉样硬化中的炎症:诊断和治疗
Giovanni Occhipinti1, Salvatore Brugaletta2,3, Antonio Abbate4
1Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Hospital Clínic de Barcelona, Barcelona, Catalunya, Spain.
炎症驱动冠状动脉样硬化,从缓慢的斑块生长到突然的心脏病发作. 通过新疗法准这种炎症,为治疗冠状动脉疾病提供了一种有前途的方法.
科学领域:
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
- 生物标志物 生物标志物
背景情况:
- 冠状动脉样硬化涉及动脉中的斑块积累,与胆固醇和吸烟,糖尿病和高血压等危险因素有关.
- 系统性炎症起着至关重要的作用,影响斑块从稳定疾病到急性冠状动脉综合征的进展.
研究的目的:
- 审查炎症生物标志物和成像,以检测冠状动脉斑块进展中的炎症.
- 探索目前和新兴的冠状动脉样硬化的抗炎疗法.
主要方法:
- 关于冠状动脉样硬化的炎症生物标志物研究的文献综述.
- 分析用于可视化动脉炎症的成像技术.
- 对研究抗炎药物治疗心血管疾病的临床试验的调查.
主要成果:
- 炎症生物标志物和成像对于评估斑块阶段和风险至关重要.
- 现有的抗炎药物显示出一些疗效,新的药物正在研究中.
- 炎症是治疗冠状动脉疾病的关键治疗点.
结论:
- 炎症是冠状动脉样硬化的主要原因,影响斑块稳定性和临床事件.
- 生物标志物和成像技术有助于风险分层和治疗监测.
- 针对炎症是预防心血管事件的重要治疗策略.
更多相关视频
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
相关概念视频
Inflammation
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
